Skip to main content
SpringerLink
Log in

Lopinavir/Ritonavir Versus Darunavir Plus Ritonavir for HIV Infection: A Cost-Effectiveness Analysis for the United States

  • Original Research Article
  • Published:
PharmacoEconomics Aims and scope Submit manuscript

Abstract

Background

The ARTEMIS trial compared first-line antiretroviral therapy (ART) with lopinavir/ritonavir (LPV/r) to darunavir plus ritonavir (DRV + RTV) for HIV-1-infected subjects. In order to fully assess the implications of this study, economic modelling extrapolating over a longer term is required.

Objective

The aim of this study was to simulate the course of HIV and its management, including the multiple factors known to be of importance in ART.

Methods

A comprehensive discrete event simulation was created to represent, as realistically as possible, ART management and HIV outcomes. The model was focused on patients for whom clinicians believed that LPV/r or DRV + RTV were good options as a first regimen. Prognosis was determined by the impact of initial treatment on baseline CD4+ T-cell count and viral load, adherence, virological suppression/failure/rebound, acquired resistance mutations, and ensuing treatment changes. Inputs were taken from trial data (ARTEMIS), literature and, where necessary, stated assumptions. Clinical measures included AIDS events, side effects, time on sequential therapies, cardiovascular events, and expected life-years lost as a result of HIV infection. The model underwent face, technical and partial predictive validation. Treatment-naive individuals similar to those in the ARTEMIS trial were modelled over a lifetime, and outcomes with first-line DRV + RTV were compared with those with LPV/r, both paired with tenofovir and emtricitabine. Up to three regimen changes were permitted. Drug prices were based on wholesale acquisition cost. Outcomes were lifetime healthcare costs (in 2011 US dollars) from the US healthcare system perspective and quality-adjusted life-years (QALYs) (discounted at 3 % per annum).

Results

Choice of LPV/r over DRV + RTV as initial ART resulted in nearly identical clinical outcomes, but distinctly different economic consequences. Starting with an LPV/r regimen potentially results in approximately US$25,000 discounted lifetime savings. Accumulated QALYs for LPV/r and DRV + RTV were 12.130 and 12.083, respectively (a 19-day difference). In sensitivity analyses, net monetary benefit ranged from US$12,000 to US$31,000, favouring LPV/r (base case US$27,762).

Conclusions

A comprehensive simulation of lifetime course of HIV in the USA indicated that using LPV/r as first-line therapy compared with DRV + RTV may result in cost savings, with similar clinical outcomes.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Hammer SM, Squires KE, Hughes MD, Grimes JM, Demeter LM, Currier JS, et al. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. AIDS Clinical Trials Group 320 Study Team. N Engl J Med. 1997;337(11):725–33.

    Article  PubMed  CAS  Google Scholar 

  2. Montaner JS, Reiss P, Cooper D, Vella S, Harris M, Conway B, et al. A randomized, double-blind trial comparing combinations of nevirapine, didanosine, and zidovudine for HIV-infected patients: the INCAS Trial. Italy, The Netherlands, Canada and Australia Study. JAMA. 1998;279(12):930–7.

    Article  PubMed  CAS  Google Scholar 

  3. Palella FJ, Delaney KM, Moorman AC, Loveless MO, Fuhrer J, Satten GA, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med. 1998;338(13):853–60.

    Article  PubMed  Google Scholar 

  4. Walensky RP, Paltiel AD, Losina E, Mercincavage LM, Schackman BR, Sax PE, et al. The survival benefits of AIDS treatment in the United States. J Infect Dis. 2006;194(1):11–9.

    Article  PubMed  Google Scholar 

  5. Braithwaite RS, Justice AC, Chang C-CH, Fusco JS, Raffanti SR, Wong JB, et al. Estimating the proportion of patients infected with HIV who will die of comorbid diseases. Am J Med. 2005;118(8):890–8.

    Article  PubMed  Google Scholar 

  6. Centers for Disease Control and Prevention (CDC). HIV United States Fact Sheet: HIV in the United States at a glance. Atlanta: CDC; 2013. http://www.cdc.gov/hiv/resources/factsheets/PDF/stats_basics_factsheet.pdf. Accessed 20 Mar 2013.

  7. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Updated 12 Feb 2013. http://aidsinfo.nih.gov/contentfiles/lvguidelines/adultandadolescentgl.pdf. Accessed 10 Mar 2013.

  8. Ortiz R, Dejesus E, Khanlou H, Voronin E, van Lunzen J, Andrade-Villanueva J, et al. Efficacy and safety of once-daily darunavir/ritonavir versus lopinavir/ritonavir in treatment-naive HIV-1-infected patients at week 48. AIDS. 2008;22(12):1389–97.

    Article  PubMed  CAS  Google Scholar 

  9. Mills AM, Nelson M, Jayaweera D, Ruxrungtham K, Cassetti I, Girard P-M, et al. Once-daily darunavir/ritonavir vs. lopinavir/ritonavir in treatment-naive, HIV-1-infected patients: 96-week analysis. AIDS. 2009;23(13):1679–88.

    Article  PubMed  CAS  Google Scholar 

  10. Hellinger FJ. The lifetime cost of treating a person with HIV. JAMA. 1993;270(4):474–8.

    Article  PubMed  CAS  Google Scholar 

  11. Hutchinson AB, Farnham PG, Dean HD, Ekwueme DU, del Rio C, Kamimoto L, et al. The economic burden of HIV in the United States in the era of highly active antiretroviral therapy: evidence of continuing racial and ethnic differences. J Acquir Immune Defic Syndr. 2006;43(4):451–7.

    Article  PubMed  Google Scholar 

  12. Schackman BR, Gebo KA, Walensky RP, Losina E, Muccio T, Sax PE, et al. The lifetime cost of current human immunodeficiency virus care in the United States. Med Care. 2006;44(11):990–7.

    Article  PubMed  Google Scholar 

  13. Simpson KN, Rajagopalan R, Dietz B. Cost-effectiveness analysis of lopinavir/ritonavir and atazanavir + ritonavir regimens in the CASTLE study. Adv Ther. 2009;26(2):185–93.

    Article  PubMed  Google Scholar 

  14. Simpson KN. Economic modeling of HIV treatments. Curr Opin HIV AIDS. 2010;5(3):242–8.

    Article  PubMed  Google Scholar 

  15. Caro JJ, Moller J, Getsios D. Discrete event simulation: the preferred technique for health economic evaluations? Value Health. 2010;13(8):1056–60.

    Article  PubMed  Google Scholar 

  16. Karnon J, Stahl J, Alan B, et al. Modeling using discrete event simulation: a report of the ISPOR-SMDM modeling good research practices task force working group 4. Value Health. 2012;15(6):821–7.

    Article  PubMed  Google Scholar 

  17. Antiretroviral Cohort Collaboration (ART-CC). Effect of baseline CD4 cell counts on the clinical significance of short-term immunologic response to antiretroviral therapy in individuals with virologic suppression. JAIDS. 2009;52:357–63.

    Google Scholar 

  18. Molina J-M, Podsadecki TJ, Johnson MA, Wilkin A, Domingo P, Myers R, et al. A lopinavir/ritonavir-based once-daily regimen results in better compliance and is non-inferior to a twice-daily regimen through 96 weeks. AIDS Res Hum Retrovir. 2007;23(12):1505–14.

    Article  PubMed  CAS  Google Scholar 

  19. Murphy RL, da Silva BA, Hicks CB, Eron JJ, Gulick RM, Thompson MA, et al. Seven-year efficacy of a lopinavir/ritonavir-based regimen in antiretroviral-naive HIV-1-infected patients. HIV Clin Trials. 2008;9(1):1–10.

    Article  PubMed  Google Scholar 

  20. Gathe J, daSilva B, Loutfy M, et al. Study M05-730 primary efficacy results at week 48: phase 3, randomized, open-label study of lopinavir–ritonavir (LPV/r) tablets once-daily (OD) vs. twice-daily (BID), co-administered with tenofovir (TDF) plus emtricitabine (FTC) in antiretroviral naïve (ARV) HIV-1-infected subjects. In: 15th Conference on retroviruses and opportunistic infections (CROI), Boston, MA; 3–6 Feb 2008.

  21. Kaletra package insert. Revision 3/2010. North Chicago: AbbVie Inc.; 2010. http://www.rxabbott.com/pdf/kaletratabpi.pdf. Accessed 15 Jul 2011.

  22. Friis-Moller N, Weber R, Reiss P, Thiebaut R, Kirk O, D’Arminio Monforte A, et al. Cardiovascular disease risk factors in HIV patients—association with antiretroviral therapy. Results from the DAD study. AIDS. 2003;17(8):1179–93.

    Article  PubMed  Google Scholar 

  23. Paterson DL, Swindells S, Mohr J, Brester M, Vergis EN, Squier C, et al. Adherence to protease inhibitor therapy and outcomes in patients with HIV infection. Ann Intern Med. 2000;133(1):21–30.

    Article  PubMed  CAS  Google Scholar 

  24. King MS, Brun SC, Kempf DJ. Relationship between adherence and the development of resistance in antiretroviral-naive, HIV-1-infected patients receiving lopinavir/ritonavir or nelfinavir. J Infect Dis. 2002;191(12):2046–52.

    Article  Google Scholar 

  25. Mannheimer S, Friedland G, Matts J, Child C, Chesney M. The consistency of adherence to antiretroviral therapy predicts biologic outcomes for human immunodeficiency virus-infected persons in clinical trials. Clin Infect Dis. 2002;34(8):1115–21.

    Article  PubMed  Google Scholar 

  26. Deeks SG, Barbour JD, Grant RM, Martin JN. Duration and predictors of CD4 T-cell gains in patients who continue combination therapy despite detectable plasma viremia. AIDS. 2002;16(2):201–7.

    Article  PubMed  Google Scholar 

  27. Gonzalez de Requena D, Bonora S, Garazzino S, Sciandra M, D’Avolio A, Raiteri R, et al. Nevirapine plasma exposure affects both durability of viral suppression and selection of nevirapine primary resistance mutations in a clinical setting. Antimicrob Agents Chemother. 2005;49(9):3966–9.

    Article  PubMed  CAS  Google Scholar 

  28. Nelson M, Girard PM, DeMasi R, et al. Adherence to darunavir/ritonavir and lopinavir/ritonavir in treatment-naïve, HIV-infected patients in ARTEMIS: 96 week data. In: 15th Annual conference of the British HIV Association, London; 8–9 Oct 2009.

  29. National Center for Infectious Diseases Division of HIV/AIDS. 1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. Atlanta: CDC; 1992. http://www.cdc.gov/mmwr/preview/mmwrhtml/00018871.htm. Accessed 20 Jul 2011.

  30. Ghani AC, de Wolf F, Ferguson NM, Donnelly CA, Coutinho R, Miedema F, et al. Surrogate markers for disease progression in treated HIV infection. J Acquir Immune Defic Syndr. 2001;28(3):226–31.

    PubMed  CAS  Google Scholar 

  31. Ghani AC, Henley WE, Donnelly CA, Mayer S, Anderson RM. Comparison of the effectiveness of non-nucleoside reverse transcriptase inhibitor-containing and protease inhibitor-containing regimens using observational databases. AIDS. 2001;15(9):1133–42.

    Article  PubMed  CAS  Google Scholar 

  32. Gebo KA, Gallant JE, Keruly JC, Moore RD. Absolute CD4 vs. CD4 percentage for predicting the risk of opportunistic illness in HIV infection. J Acquir Immune Defic Syndr. 2004;36(5):1028–33.

    Article  PubMed  Google Scholar 

  33. Rahim S, Fredrick LM, da Silva BA, Bernstein B, King MS. Geographic and temporal trends of transmitted HIV-1 drug resistance among antiretroviral-naive subjects screening for two clinical trials in North America and Western Europe. HIV Clin Trials. 2009;10(2):94–103.

    Article  PubMed  Google Scholar 

  34. Hill A, Pulido F, Arribas J, Moecklinghoff C. Prevalence of IAS-USA PI mutations during episodes of viremia in the MONET trial of darunavir/ritonavir, with or without nucleoside analogues. In: 8th European HIV drug resistance workshop, 2010, Sorrento; 17–19 Mar 2010.

  35. Cahn P, Fourie J, Grinsztejn B, Hodder S, Molina J-M, Ruxrungtham K, et al. Week 48 analysis of once-daily vs. twice-daily darunavir/ritonavir in treatment-experienced HIV-1-infected patients. AIDS. 2011;25(7):929–39.

    Article  PubMed  CAS  Google Scholar 

  36. Ghosn J, Flandre P, Cohen-Codar I, Girard PM, Chaix ML, Raffi F, et al. Long-term (96-week) follow-up of antiretroviral-naive HIV-infected patients treated with first-line lopinavir/ritonavir monotherapy in the MONARK trial. HIV Med. 2010;11(2):137–42.

    Article  PubMed  CAS  Google Scholar 

  37. Anderson KM, Odell PM, Wilson PW, Kannel WB. Cardiovascular disease risk profiles. Am Heart J. 1991;121(1 Part 2):293–8.

    Article  PubMed  CAS  Google Scholar 

  38. AnalySource® Online. http://www.firstdatabank.com/Products/analysource.aspx? Accessed 20 May 2011 (by subscription only).

  39. Andrulis DP, Weslowski VB, Hintz E, Spolarich AW. Comparisons of hospital care for patients with AIDS and other HIV-related conditions. JAMA. 1992;267(18):2482–6.

    Article  PubMed  CAS  Google Scholar 

  40. Caro JJ, Stillman IO, Danel A, Getsios D, McEwan P. Cost effectiveness of rimonabant use in patients at increased cardiometabolic risk: estimates from a Markov model. J Med Econ. 2007;10:239–54.

    Article  Google Scholar 

  41. Huang JS, Becerra K, Fernandez S, Lee D, Mathews WC. The impact of HIV-associated lipodystrophy on healthcare utilization and costs. AIDS Res Ther. 2008;5:14.

    Article  PubMed  Google Scholar 

  42. US Bureau of Labor Statistics. Consumer price index, medical care. Washington, DC: US Bureau of Labor Statistics. Series Id: CUUR0000SAM2 Not Seasonally Adjusted. Area: U.S. city average. Item: Medical care services. Base Period: 1982-84=100. http://data.bls.gov/. Accessed 8 May 2011.

  43. Dolan P. Modeling valuations for EuroQol health states. Med Care. 1997;35(11):1095–108.

    Article  PubMed  CAS  Google Scholar 

  44. Moore RD, Chaisson RE. Cost-utility analysis of prophylactic treatment with oral ganciclovir for cytomegalovirus retinitis. J Acquir Immune Defic Syndr Hum Retrovirol. 1997;16(1):15–21.

    Article  PubMed  CAS  Google Scholar 

  45. Simpson KN, Dietz B, Baran RW, Garren KW, Riddler SA, Bhor M, et al. Economic modeling of the combined effects of HIV-disease, cholesterol and lipoatrophy based on ACTG 5142 trial data. Cost Eff Resour Alloc. 2011;9:5.

    Article  PubMed  Google Scholar 

  46. Bayoumi AM, Redelmeier DA. Preventing Mycobacterium avium complex in patients who are using protease inhibitors: a cost-effectiveness analysis. AIDS. 1998;12(12):1503–12.

    Article  PubMed  CAS  Google Scholar 

  47. Eddy DM, Hollingworth W, Caro JJ, et al. Model transparency and validation: a report of the ISPOR-SMDM modeling good research practices task force working group 7. Value Health. 2012;15:845–50.

    Article  Google Scholar 

  48. Kaplan SS, Hicks CB. Safety and antiviral activity of lopinavir/ritonavir-based therapy in human immunodeficiency virus type 1 (HIV-1) infection. J Antimicrob Chemother. 2005;56(2):273–6.

    Article  PubMed  CAS  Google Scholar 

  49. Hicks C, King MS, Gulick RM, White AC, Eron JJ, Kessler HA, et al. Long-term safety and durable antiretroviral activity of lopinavir/ritonavir in treatment-naive patients: 4 year follow-up study. AIDS. 2004;18(5):775–9.

    Article  PubMed  CAS  Google Scholar 

  50. Grosse SD. Assessing cost-effectiveness in healthcare: history of the $50,000 per QALY threshold. Expert Rev Pharmacoecon Outcomes Res. 2008;8(2):165–78.

    Article  PubMed  Google Scholar 

  51. Weinstein MC. How much are Americans willing to pay for a quality-adjusted life year? Med Care. 2008;46(4):343–5.

    Article  PubMed  Google Scholar 

  52. Briggs A, Weinstein M, Fenwick E, et al. Model parameter estimation and uncertainty: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force Working Group-6. Value Health. 2012;32(5):722–32.

    Google Scholar 

  53. Glick HA. Sampling uncertainty: what we are doing right and where we are going wrong. In: ISPOR western pharmacoeconomics conference, 2009, Pasadena, CA; 18–20 Mar 2009.

  54. Caro J, Briggs A, Siebert U, et al. Modeling good research practices—overview: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force-1. Value Health. 2012;15(6):796–803.

    Article  PubMed  Google Scholar 

  55. Mocroft A, Lundgren JD. Starting highly active antiretroviral therapy: why, when and response to HAART. J Antimicrob Chemother. 2004;54(1):10–3.

    Article  PubMed  CAS  Google Scholar 

  56. Brogan AJ, Mrus J, Hill A, Sawyer AW, Smets E. Comparative cost-efficacy analysis of darunavir/ritonavir and other ritonavir-boosted protease inhibitors for first-line treatment of HIV-1 infection in the United States. HIV Clin Trials. 2010;11(3):133–44.

    Article  PubMed  CAS  Google Scholar 

  57. Mauskopf J, Brogan A, Martin S, Smets E. Cost effectiveness of darunavir/ritonavir in highly treatment-experienced, HIV-1-infected adults in the USA. Pharmacoeconomics. 2010;28(Suppl 1):83–105.

    Article  PubMed  Google Scholar 

  58. Moeremans K, Annemans L, Lothgren M, Allegri G, Wyffels V, Hemmet L, et al. Cost effectiveness of darunavir/ritonavir 600/100 mg bid in protease inhibitor-experienced, HIV-1-infected adults in Belgium, Italy, Sweden and the UK. Pharmacoeconomics. 2010;28(Suppl 1):107–28.

    Article  PubMed  Google Scholar 

  59. Moeremans K, Hemmett L, Hjelmgren J, Allegri G, Smets E. Cost effectiveness of darunavir/ritonavir 600/100 mg bid in treatment-experienced, lopinavir-naive, protease inhibitor-resistant, HIV-infected adults in Belgium, Italy, Sweden and the UK. Pharmacoeconomics. 2010;28(Suppl 1):147–67.

    Article  PubMed  Google Scholar 

  60. Siebert U, Alagoz O, Bayoumi AM, et al. State-transition modeling: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force Working Group-3. Value Health. 2012;15(6):812–20.

    Article  PubMed  Google Scholar 

  61. Roberts M, Russel L, Paltiel AD, et al. Conceptualizing a model: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force Working Group-2. Value Health. 2012;15(6):804–11.

    Article  PubMed  Google Scholar 

  62. Stanford University. HIV Drug Resistance Database. HIVdb Program: genotypic resistance interpretation algorithm. Stanford: HIVDB; 2011. http://sierra2.stanford.edu/sierra/servlet/JSierra. Accessed 17 Feb 2011.

  63. Barros ZM, de Alencar Ximenes RA, Miranda-Filho DB, de Albuquerque MdFPM, Melo HRL, Carvalho EH, et al. Comparison between the Framingham and prospective cardiovascular of Munster scores for risk assessment of coronary heart disease in human immunodeficiency virus-positive patients in Pernambuco, Brazil. Metab Syndr Relat Disord. 2010;8(6):489–97.

    Article  PubMed  Google Scholar 

  64. Falcone EL, Mangili A, Skinner S, Alam A, Polak JF, Wanke CA. Framingham risk score and early markers of atherosclerosis in a cohort of adults infected with HIV. Antivir Ther. 2011;16(1):1–8.

    Article  PubMed  CAS  Google Scholar 

  65. Friis-Moller N, Thiebaut R, Reiss P, Weber R, Monforte ADA, De Wit S, et al. Predicting the risk of cardiovascular disease in HIV-infected patients: the data collection on adverse effects of anti-HIV drugs study. Eur J Cardiovasc Prev Rehabil. 2010;17(5):491–501.

    Article  PubMed  Google Scholar 

  66. Johnson M, Grinsztejn B, Rodriguez C, Coco J, DeJesus E, Lazzarin A, et al. 96-week comparison of once-daily atazanavir/ritonavir and twice-daily lopinavir/ritonavir in patients with multiple virologic failures. AIDS. 2006;20(5):711–8.

    Article  PubMed  CAS  Google Scholar 

  67. Madruga JV, Berger D, McMurchie M, Suter F, Banhegyi D, Ruxrungtham K, et al. Efficacy and safety of darunavir–ritonavir compared with that of lopinavir–ritonavir at 48 weeks in treatment-experienced, HIV-infected patients in TITAN: a randomised controlled phase III trial. Lancet. 2007;370(9581):49–58.

    Article  PubMed  CAS  Google Scholar 

  68. Dragsted UB, et al. A phase IV randomised, open-label, multicentre trial to evaluate safety and efficacy of indinavir/ritonavir (800/100 mg BID) vs. saquinavir/ritonavir (1000/100 mg BID) in adult HIV-1 infection: the MaxCmin 1 trial. In: 8th ECCATH, Athens; 29–31 Oct 2001.

  69. Madruga JV, Cahn P, Grinsztejn B, Haubrich R, Lalezari J, Mills A, et al. Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-1: 24-week results from a randomised, double-blind, placebo-controlled trial. Lancet. 2007;370(9581):29–38.

    Article  PubMed  CAS  Google Scholar 

  70. Steigbigel RT, Cooper DA, Teppler H, Eron JJ, Gatell JM, Kumar PN, et al. Long-term efficacy and safety of Raltegravir combined with optimized background therapy in treatment-experienced patients with drug-resistant HIV infection: week 96 results of the BENCHMRK 1 and 2 Phase III trials. Clin Infect Dis. 2010;50(4):605–12.

    Article  PubMed  CAS  Google Scholar 

  71. Lexiva package insert. http://viivhealthcare.com/~/media/Files/G/GlaxoSmithKline-Plc/pdfs/us_lexiva.pdf. Accessed 1 Apr 2011.

  72. Hicks CB, Cahn P, Cooper DA, Walmsley SL, Katlama C, Clotet B, et al. Durable efficacy of tipranavir–ritonavir in combination with an optimised background regimen of antiretroviral drugs for treatment-experienced HIV-1-infected patients at 48 weeks in the Randomized Evaluation of Strategic Intervention in multi-drug reSistant patients with Tipranavir (RESIST) studies: an analysis of combined data from two randomised open-label trials. Lancet. 2006;368(9534):466–75.

    Article  PubMed  CAS  Google Scholar 

  73. Lalezari JP, Henry K, O’Hearn M, Montaner JSG, Piliero PJ, Trottier B, et al. Enfuvirtide, an HIV-1 fusion inhibitor, for drug-resistant HIV infection in North and South America. N Engl J Med. 2003;348(22):2175–85.

    Article  PubMed  CAS  Google Scholar 

  74. Trotta MP, Cozzi-Lepri A, Ammassari A, Vecchiet J, Cassola G, Caramello P, et al. Rate of CD4+ cell count increase over periods of viral load suppression: relationship with the number of previous virological failures. Clin Infect Dis. 2010;51(4):456–64.

    Article  PubMed  Google Scholar 

  75. Simpson KN, Luo MP, Chumney E, Sun E, Brun S, Ashraf T. Cost-effectiveness of lopinavir/ritonavir versus nelfinavir as the first-line highly active antiretroviral therapy regimen for HIV infection. HIV Clin Trials. 2004;5(5):294–304.

    Article  PubMed  Google Scholar 

  76. Simpson K. Event data for South Carolina Medicaid patients from 2002 and 2003. Columbia: S.C. Budget and Control Board, Office of Research & Statistics; 2005.

  77. 2007 and 2008 HCUP state inpatient data for CA, FL, MA, MD, NJ, WA. State Inpatient Databases (SID), Healthcare Cost and Utilization Project (HCUP), Agency for Healthcare Research and Quality. http://www.hcup-us.ahrq.gov/db/state/siddbdocumentation.jsp. Accessed 21 Mar 2013.

  78. Health Care Finance Review/2009 Statistical Supplement. http://www.cms.gov/MedicareMedicaidStatSupp/LT/itemdetail.asp?filterType=none&filterByDID=0&sortByDID=2&sortOrder=descending&itemID=CMS1232665&intNumPerPage=10. Accessed 29 Nov 2010.

Download references

Acknowledgments

This study was funded by Abbott Laboratories. K.N.S. was a paid consultant. P.P.P., J.M., K.M.-W. and J.J.C. were employees of a consultancy (United BioSource Corporation) that received funds for carrying out this work. R.W.B., B.D. and W.W. were all Abbott employees when this research was conducted. B.D., W.W. and R.W.B. hold stock in Abbott Laboratories. K.N.S., B.D., R.W.B. and J.J.C. conceived the original idea for the research. J.M., J.J.C., P.P.P. and K.N.S. developed the conceptual model. P.P.P., K.M.-W. and K.N.S. performed the data extraction for the evidence tables. W.W., B.D. and R.W.B. reviewed the conceptual model and evidence. J.M. and P.P.P. programmed the model and performed the analyses. P.P.P., J.M. and K.M.-W. drafted the manuscript. All authors reviewed, edited and made significant contributions to the final manuscript. K.N.S. acts as guarantor for the overall content.

Author information

Authors and Affiliations

  1. Department of Health Leadership and Management, College of Health Professions, Medical University of South Carolina, 151B Rutledge Ave., Room 412, Charleston, SC, 29425, USA

    Kit N. Simpson

  2. Medical Practice Evaluation Center, Massachusetts General Hospital, Boston, MA, USA

    Pamela P. Pei

  3. United BioSource Corporation, London, UK

    Jörgen Möller

  4. Abbott Laboratories, Abbott Park, IL, USA

    Robert W. Baran & William Woodward

  5. Abbott GmbH & Co. KG, Ludwigshafen, Germany

    Birgitta Dietz

  6. Institute for Clinical and Economic Review, Massachusetts General Hospital, Boston, MA, USA

    Kristen Migliaccio-Walle

  7. United BioSource Corporation, Lexington, MA, USA

    Pamela P. Pei, Kristen Migliaccio-Walle & J. Jaime Caro

  8. Faculty of Medicine, McGill University, Montreal, QC, Canada

    J. Jaime Caro

Authors
  1. Kit N. Simpson
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Pamela P. Pei
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Jörgen Möller
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Robert W. Baran
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Birgitta Dietz
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. William Woodward
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Kristen Migliaccio-Walle
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. J. Jaime Caro
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Kit N. Simpson.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Simpson, K.N., Pei, P.P., Möller, J. et al. Lopinavir/Ritonavir Versus Darunavir Plus Ritonavir for HIV Infection: A Cost-Effectiveness Analysis for the United States. PharmacoEconomics 31, 427–444 (2013). https://doi.org/10.1007/s40273-013-0048-3

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40273-013-0048-3

Keywords

Search

Navigation